Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia

SIMPLE SUMMARY: Tyrosine kinase inhibitors (TKIs) have dramatically improved the treatment of chronic myeloid leukemia (CML). Recently, TKIs were discontinued in patients with CML with deep molecular remission, and some patients have been reported to be able to maintain long-term treatment-free remi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujioka, Yuki, Sugiyama, Daisuke, Matsumura, Itaru, Minami, Yosuke, Miura, Masatomo, Atsuta, Yoshiko, Ohtake, Shigeki, Kiyoi, Hitoshi, Miyazaki, Yasushi, Nishikawa, Hiroyoshi, Takahashi, Naoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657169/
https://www.ncbi.nlm.nih.gov/pubmed/34885012
http://dx.doi.org/10.3390/cancers13235904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657169/
https://www.ncbi.nlm.nih.gov/pubmed/34885012
http://dx.doi.org/10.3390/cancers13235904

Ejemplares similares